Sensitivity of serum S100B protein as a disease activity marker in Egyptian patients with vitiligo (case-control study)

2020 ◽  
pp. 1-8
Author(s):  
Fatma H. Shabaka ◽  
Laila A. Rashed ◽  
Marwa Said ◽  
Lobna Ibrahim
Keyword(s):  
Disease Activity ◽  
Case Control Study ◽  
Case Control ◽  
S100b Protein ◽  
Serum S100b ◽  
Egyptian Patients ◽  
Activity Marker ◽  
Control Study

scholarly journals Serum C1q concentration is associated with disease activity in Chinese Takayasu arteritis patients: A case‐control study

2021 ◽  
Vol 4 (2) ◽  
Author(s):  
Si Chen ◽  
Haixia Luan ◽  
Jianxun He ◽  
Yan Wang ◽  
Xiaoli Zeng ◽  
...  
Keyword(s):  
Disease Activity ◽  
Takayasu Arteritis ◽  
Case Control Study ◽  
Case Control ◽  
Control Study

scholarly journals Hemophagocytic Lymphohistiocytosis: Prevalence, Risk Factors, Outcome, and Outcome-related Factors in Adult Idiopathic Inflammatory Myopathies

2019 ◽  
Vol 47 (10) ◽  
pp. 1532-1540 ◽  
Author(s):  
Junyu Liang ◽  
Danyi Xu ◽  
Chuanyin Sun ◽  
Weiqian Chen ◽  
Heng Cao ◽  
...  
Keyword(s):  
Risk Factors ◽  
Disease Activity ◽  
Case Control Study ◽  
Case Control ◽  
Short Term ◽  
Related Factors ◽  
Term Outcome ◽  
Factors Influencing ◽  
Short Term Outcome ◽  
Control Study

Objective.To clarify the prevalence, risk factors, outcome, and outcome-related factors of hemophagocytic lymphohistiocytosis (HLH) in patients with dermatomyositis (DM), polymyositis (PM), or clinically amyopathic dermatomyositis (CADM).Methods.Data of patients with DM, PM, or CADM who were admitted to the First Affiliated Hospital of Zhejiang University from February 2011 to February 2019 were retrospectively collected. Patients diagnosed with HLH constituted the case group. A 1:4 case-control study was performed to identify risk factors for HLH in patients with DM, PM, or CADM through comparison, univariate, and multivariate logistic regression analysis. Intragroup comparison was made among patients with HLH to identify factors influencing unfavorable short-term outcome.Results.HLH was a rare (4.2%) but fatal (77.8%) complication in patients with DM, PM, or CADM. The retrospective case-control study revealed that higher on-admission disease activity (p = 0.008), acute exacerbation of interstitial lung disease (AE-ILD, p = 0.002), and infection (p = 0.002) were risk factors for complication of HLH in patients with DM, PM, or CADM. The following intragroup comparison showed that higher on-admission disease activity (p = 0.035) and diagnosis of CADM (p = 0.039) might influence the short-term outcome of patients with HLH. However, no risk factor was identified after false discovery rate correction.Conclusion.In this study, secondary HLH was a fatal complication, with higher on-admission disease activity, AE-ILD, and infection working as risk factors. The underlying role of infection and autoimmune abnormality in HLH in connective tissue disease was subsequently noted. Clinical factors influencing the short-term outcome of patients with secondary HLH require further study.

scholarly journals Simultaneous Treatment with Subcutaneous Injection of Golimumab and Intra-articular Injection of Triamcinolone Acetonide (K-Method) in Patients with Rheumatoid Arthritis Undergoing Switching of Biologics: Retrospective Case–Control Study

2016 ◽  
Vol 9 ◽  
pp. CMAMD.S38442
Author(s):  
Katsuaki Kanbe ◽  
Junji Chiba ◽  
Yasuo Inoue ◽  
Masashi Taguchi ◽  
Akiko Yabuki ◽  
...  
Keyword(s):  
Disease Activity ◽  
Case Control Study ◽  
Activity Index ◽  
Disease Activity Index ◽  
Case Control ◽  
Control Group ◽  
Retrospective Case ◽  
Simultaneous Treatment ◽  
Method Group ◽  
Control Study

Background Tight control of severe rheumatoid arthritis (RA) in patients with high disease activity, even when using biologics, is sometimes difficult using a treat-to-target strategy. Switching from one biologic to another is associated with lower efficacy than that in treatment-naive cases. We developed the K-method that involves simultaneous treatment with golimumab and intra-articular joint injection of triamcinolone acetonide (TA) in patients undergoing switching of biologics. We performed this retrospective case–control study to investigate the efficacy of achieving an immediate treatment response using the K-method. Methods This study involved 20 patients with RA (control group, 10 patients; K-method group, 10 patients). Patients in the control group were switched to golimumab from other biologics without intra-articular injection of TA. The K-method involved injection of 1 mL of TA (40 mg/mL) and 2 mL of 1% lidocaine hydrochloride into swollen or painful joints on the same day as golimumab treatment. A quick response one day after treatment was compared between the two groups according to the disease activity score 28 based on C-reactive protein (DAS28 CRP), clinical disease activity index (CDAI), simplified disease activity index (SDAI), European League Against Rheumatism (EULAR) response, and remission rate. These parameters were investigated for 24 weeks. Results The K-method group showed significant improvements in DAS28 CRP, CDAI, and SDAI at one day, 12 weeks, and 24 weeks compared with the control group. The number of swollen and tender joints and the patient and doctor global visual analog scale scores were also significantly different between the two groups. The remission rates based on DAS28 CRP were 30% at one day, 50% at 12 weeks, and 60% at 24 weeks in the K-method group. The EULAR good/moderate response rates were 80% at one day, 90% at 12 weeks, and 90% at 24 weeks in the K-method group; however, these rates were only 10%, 40%, and 40%, respectively, in the control group. No adverse events occurred in either group. Conclusion Simultaneous treatment with biologics and intra-articular injection of TA is useful for cases involving switching of biologics for RA. This strategy is safe and practical for RA treatment.

scholarly journals Is Ultrasound a Better Target than Clinical Disease Activity Scores in Rheumatoid Arthritis with Fibromyalgia? A Case-Control Study

PLoS ONE ◽  
2015 ◽  
Vol 10 (3) ◽  
pp. e0118620 ◽  
Author(s):  
Rafael Mendonça da Silva Chakr ◽  
João Carlos Tavares Brenol ◽  
Marina Behar ◽  
José Alexandre Mendonça ◽  
Charles Lubianca Kohem ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Case Control Study ◽  
Case Control ◽  
Clinical Disease ◽  
Clinical Disease Activity ◽  
Control Study

scholarly journals Patients with rheumatoid arthritis with moderate or high disease activity benefit from multidisciplinary rehabilitation: a nested case-control study

2021 ◽  
Author(s):  
◽  
Bernardo Matos da Cunha ◽  
Bruno Silva de Araújo Ferreira ◽  
Camila Sodré Mendes Barros ◽  
Jesiniana Rodrigues Silva ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Case Control Study ◽  
Health Assessment ◽  
Case Control ◽  
Rehabilitation Program ◽  
Before And After ◽  
Post Hoc ◽  
Nested Case Control ◽  
Control Study

AbstractBackgroundrheumatologists recognize the importance of rehabilitation in patients with rheumatoid arthritis (RA), but they are not confident if patients with significant disease activity would benefit from it. Objective: To verify if rheumatoid arthritis patients with moderate to severe inflammatory activity (MHA) improve functional capacity (FC) after a comprehensive rehabilitation program.MethodsNested case-control study. RA patients who completed a rehabilitation program between June 2014 and December 2017 were included. The interventions were prescribed according to the rehabilitation team’s discretion. FC was assessed with Health Assessment Questionnaire Disability Index (HAQ) and compared between before and after interventions. The group which improved at least 50% in CDAI was compared to the group which achieved <50%.ResultsWe included 46 patients with complete HAQ and baseline CDAI data, with a mean age of 53.6 years and a mean disease duration of 11.8 years. HAQ and CDAI improved on average 0.481 (± 0.500) and 14.2 (± 16.7), respectively. Patients who improved CDAI tended to have a greater mean HAQ difference (0.6 vs. 0.3; p = 0.058). Conversely, patients who did not improve disease activity had a HAQ reduction of 0.3 (± 0.4). Post-hoc analysis was performed on the group of 9 patients with baseline CDAI ≤10. A mean baseline CDAI of 5.2 and a mean HAQ difference of 0.319 (0.079; 0.56; p = 0.016) were found.ConclusionsAfter rehabilitation, RA patients with sustained MHA improved FC similarly to patients with baseline mild activity or remission. Thus, patients with RA and MHA may benefit from rehabilitation concurrently with drug treatment. This study suggests that the range of improvement in FC with rehabilitation appears to have an additive effect to the drug therapy.

Sign in / Sign up

Export Citation Format

Share Document